X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Gossamer intends to use the net proceeds to fund the ongoing development and commercialization of GB002 (seralutinib), a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, for the treatment of pulmonary arterial hypertension (PAH).
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GB002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: New Enterprise Associates
Deal Size: $212.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 20, 2023
Details:
The FDA has now placed a clinical hold on all trials of GB5121, which was being tested for primary central nervous system lymphoma. Now, all work related to GB5121 has been discontinued and the ongoing studies shelved.
Lead Product(s): GB5121
Therapeutic Area: Oncology Product Name: GB5121
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
The efficacy results generated with GB002 (seralutinib) in the context of a favorable safety and tolerability profile highlight compelling potential differentiation for seralutinib as an anti-proliferative, anti-inflammatory, and anti-fibrotic therapeutic candidate.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GB002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
Gossamer intends to use the net proceeds from the proposed financing to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GB002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 13, 2022
Details:
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with WHO Group 1 PAH who are Functional Class II and III.
Lead Product(s): Seralutinib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Neither statistically significant nor clinically meaningful differences were observed for primary endpoint and secondary endpoints, including histologic and mucosal healing endpoints, for either GB004 treatment group relative to placebo at week 12.
Lead Product(s): GB004
Therapeutic Area: Gastroenterology Product Name: GB004
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Presentation includes clinical and biomarker data from the ongoing GB1275 Phase 1/2 clinical trial, KEYNOTE-A36, in advanced solid tumors and corresponding presentations from Johanna Bendell, M.D. and Wells Messersmith, M.D.
Lead Product(s): GB1275,Pembrolizumab
Therapeutic Area: Oncology Product Name: GB1275
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
The primary endpoint of the trial was not met, though consistent and meaningful numeric reductions in the odds of asthma worsening as compared to placebo were observed across all GB001 groups.
Lead Product(s): GB001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Gossamer Bio will present data relevant to GB004 at United European Gastroenterology Virtual Week 2020, which takes place from October 11th through 13th.
Lead Product(s): GB004
Therapeutic Area: Gastroenterology Product Name: GB004
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020.
Lead Product(s): GB001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
